Clincosm LogoSign in Get a demo

Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian Cancer

Sponsor
Hellenic Cooperative Oncology Group (Other)
Overall Status
Recruiting
CT.gov ID
NCT04752865
Collaborator
(none)
50
Enrollment
1
Location
70.6
Anticipated Duration (Months)
0.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

EFFECTS OF CYTOTOXIC CHEMOTHERAPY AND PARP INHIBITION ON THE GENOMIC CONTEXTURE OF OVARIAN CANCER: TR_NACT_OV/17 In order to approach the above open questions, ultimately aiming in understanding the effects of cancer drugs on tumor biology and hence in selecting the proper drugs for the patients in the context of Precision Medicine, the objective of this study is to study the genomic characteristics of ovarian tumors before and after treatment with classic neoadjuvant chemotherapy (NACT) and with the more recently approved PARP inhibitor olaparib.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    50 participants
    Observational Model:
    Other
    Time Perspective:
    Retrospective
    Official Title:
    Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian Cancer
    Actual Study Start Date :
    Feb 9, 2018
    Anticipated Primary Completion Date :
    Dec 29, 2022
    Anticipated Study Completion Date :
    Dec 29, 2023

    Outcome Measures

    Primary Outcome Measures

    1. assesment of genomic characteristics of ovarian tumors at the diagnosis [4 years]

    2. assesment of genomic characteristics of ovarian tumors after treatment with neoadjuvant platinum-based chemotherapy [4 years]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • ovarian cancer eligible for neoadjuvant chemotherapy
    Exclusion Criteria:

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Adamantia Nikolaidi Athens Greece 11524

    Sponsors and Collaborators

    • Hellenic Cooperative Oncology Group

    Investigators

    • Study Chair: Adamantia Nikolaidi, HECOG

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Hellenic Cooperative Oncology Group
    ClinicalTrials.gov Identifier:
    NCT04752865
    Other Study ID Numbers:
    • TR_NACT_OV/17
    First Posted:
    Feb 12, 2021
    Last Update Posted:
    Aug 10, 2022
    Last Verified:
    Aug 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Ovarian Neoplasms
    Carcinoma, Ovarian Epithelial

    Study Results

    No Results Posted as of Aug 10, 2022